AVENTUS Thrombectomy System
Acute Intermediate-Risk Pulmonary Embolism
ApprovedActive
Key Facts
About Inquis Medical
Inquis Medical is a commercial-stage medical device company focused on transforming the treatment of pulmonary embolism through its intelligent AVENTUS Thrombectomy System. The system, which received FDA 510(k) clearance in June 2025, combines precision aspiration, real-time tissue sensing, and integrated blood return in a single catheter, aiming to improve procedural efficiency and patient outcomes. Backed by a $75 million Series C financing and strong clinical data from its AVENTUS IDE trial, the company is positioned to scale commercial adoption in the large and growing VTE intervention market.
View full company profile